George Medicines appoints Amy Carroll as Senior Vice President of Medical Affairs

George Medicines appoints Amy Carroll as Senior Vice President of Medical Affairs

London, UK, 3 February 2025 – George Medicines, a late-stage biopharmaceutical firm centered on addressing vital unmet wants in cardiometabolic illness, immediately proclaims the appointment of Amy Carroll, Ph.D., as Senior Vice President of Medical Affairs, efficient instantly.

Amy brings over 20 years’ expertise in medical affairs from main international pharmaceutical corporations, the place she has efficiently constructed and directed medical affairs groups, main product launches throughout a number of therapeutic areas together with cardiovascular and metabolic ailments. Amy joins George Medicines from Lexicon Prescription drugs the place she was Vice President, Head of Medical Affairs, serving as a key material knowledgeable for inner and exterior collaborations in cardiorenal and metabolic ailments. Throughout her time there, the corporate launched its first-in class SGLT1/2 inhibitor, sotagliflozin, for the therapy of coronary heart failure.

Previous to Lexicon Prescription drugs, Amy held senior medical affairs positions at a number of pharmaceutical corporations together with Bristol Myers Squibb, Janssen Prescription drugs and Zealand Pharma, the place she constructed and led medical affairs groups, creating strategic partnerships with key opinion leaders, and supported a number of profitable product launches. Amy holds a Ph.D. in biochemistry and molecular biology from the College of Maine and a B.A. in biology from the College of San Diego.

Mark Mallon, Chief Govt Officer of George Medicines, stated: “Amy’s in depth observe file inside pharma, main medical affairs features and exterior stakeholder engagement will likely be invaluable to George Medicines and important in our actions for the commercialization of GMRx2. We’re delighted to welcome her to the workforce.”

Amy Carroll, Ph.D., Senior Vice President of Medical Affairs at George Medicines, stated: “I’m excited to hitch George Medicines at such a pivotal time in its improvement. The corporate’s lead candidate, GMRx2, has the potential to play an important function in addressing the worldwide burden of hypertension and enhancing affected person outcomes. I sit up for working with the workforce to appreciate its full potential.”

Ends

About George Medicines

George Medicines is a late-stage biopharmaceutical firm addressing vital unmet want within the therapy of cardiometabolic ailments with revolutionary mixtures of best-in-class present therapies, designed for optimum efficacy and security.

Combining best-in-class molecules from present medicines in novel low-dose formulations, George Medicines is creating revolutionary and proprietary therapies to be extra efficacious, safer and accessible than presently out there therapy choices. These multi-mechanism, single-pill mixtures supply the potential to convey vital enhancements in scientific outcomes and remedy adherence in sufferers with cardiometabolic problems, together with hypertension and diabetes, every of which stay the main causes of untimely loss of life and incapacity worldwide.

For extra info, please go to www.george-medicines.com.

Media contacts

ICR Healthcare
David Daley, Lindsey Neville, Tom Daniel
[email protected]; Tel: +44 (0) 203 709 5700